New treatment strategy: switching from long-term entecavir to peginterferon alfa-2a induces HBeAg seroconversion/HBsAg clearance in patients with HBeAg-positive chronic hepatitis B
单位：[1]Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Wuhan 430074, Peoples R China;华中科技大学同济医学院附属同济医院[2]Fourth Mil Med Univ, Tangdu Hosp, Xian 710032, Peoples R China;[3]Fujian Med Univ, Hosp 1, Fuzhou, Peoples R China;[4]Cent S Univ, Xiangya Hosp, Changsha, Hunan, Peoples R China;[5]Nanfang Med Univ, Nanfang Hosp, Guangzhou, Guangdong, Peoples R China;[6]Sichuan Univ, W China Hosp, Chengdu 610064, Peoples R China;四川大学华西医院[7]Zhejiang Univ, Hosp 1, Hangzhou 310003, Zhejiang, Peoples R China;浙江大学医学院附属第一医院[8]Shanghai Roche Pharmaceut Co Ltd, Shanghai, Peoples R China
第一作者单位：[1]Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Wuhan 430074, Peoples R China;
推荐引用方式(GB/T 7714)：
Ning Qin,Han Meifang,Sun Yongtao,et al.New treatment strategy: switching from long-term entecavir to peginterferon alfa-2a induces HBeAg seroconversion/HBsAg clearance in patients with HBeAg-positive chronic hepatitis B[J].HEPATOLOGY.2012,56:300A-301A.
APA：
Ning, Qin,Han, Meifang,Sun, Yongtao,Jiang, Jia-ji,Tan, Deming...&Zhao, Mianzhi.(2012).New treatment strategy: switching from long-term entecavir to peginterferon alfa-2a induces HBeAg seroconversion/HBsAg clearance in patients with HBeAg-positive chronic hepatitis B.HEPATOLOGY,56,
MLA：
Ning, Qin,et al."New treatment strategy: switching from long-term entecavir to peginterferon alfa-2a induces HBeAg seroconversion/HBsAg clearance in patients with HBeAg-positive chronic hepatitis B".HEPATOLOGY 56.(2012):300A-301A
医学